Tuesday’s biggest gaining and declining stocks

Palm Beach, FL 5/8/12 (StreetBeat) -- The following companies made notable moves in U.S. trading on Tuesday:

Gainers

FreightCar America Inc. (Nasdaq: RAIL +2.55%) rose 10% after the firm said Tuesday that its first-quarter profit came in at about $10 million, or 81 cents, versus a $1.3 million, or 11 cents a share, loss a year ago.

GTX Inc. (Nasdaq: GTXI +14.52%) rose 15% after it said the U.S. Food and Drug Administration has lifted its hold on clinical trials for the potential advanced prostate cancer and hormonal treatment Capesaris.

Decliners

Electronic Arts Inc. (Nasdaq: EA -6.87%) declined 5%. The game maker said it expects fiscal first-quarter adjusted revenue of $500 million on an adjusted loss of 40 cents to 45 cents a share. Analysts polled by FactSet Research were looking for a loss of 33 cents a share on $581 million in revenue.

Shares of Fossil Inc. (Nasdaq: FOSL -32.93%) fell more than 29% after the firm said its first-quarter earnings rose 4.2%, but a softening European economy contributed to the watch and fashion-accessories retailer’s slower-than-expected sales growth.

Mako Surgical Corp. (Nasdaq: MAKO -36.50%) dropped 37% after the surgical products maker said its first-quarter results came in at the low end of expectations. The company also pared back its 2012 sales projections for its key robotic arm systems to a range of 52 to 58, down from its earlier forecast of 56 to 62 systems.

Rackspace Hosting Inc.’s (NYSE: RAX -12.79%) shares dropped 14% after the company’s first-quarter earnings of 17 cents a share came in a penny below Wall Street’s projection.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

GTx (Nasdaq: GTXI) takes hit with delay of Capesaris trials, greater net loss

Tallahassee, FL 2/21/12 (StreetBeat) -- Shortly after receiving news from the U.S. Food and Drug Administration that clinical trials for its Capesaris drug would be put on hold, Memphis-based pharmaceutical company GTx Inc. (Nasdaq: GTXI) reported a net loss of $10.7 million for the fourth quarter of 2011, compared to a loss of $7.5 million in the fourth quarter of 2010.

Capesaris, which is used to treat prostate cancer, was in its Phase II clinical trial, was put on hold after the company reported an increase in blood clots in subjects participating in the trial. The FDA announced the hold on Feb. 17, according to a GTx statement.

GTx reported revenue of $14.7 million for year end 2011, a 75 percent decline from $60.6 million the company reported at the end of 2010. However, the company’s revenue was $1.8 million in the fourth quarters of 2011 and 2010, based on sales of the company’s breast cancer drug Fareston.

Annual revenue included $6.7 million in sales for Fareston and collaboration revenue from the company’s previous partnership with French drug company Ipsen, which brought in revenue of $8.1 million.

GTx continues to develop Ostarine, a drug that is used to treat non-small cell lung cancer. The company changed the drug’s name to Enobosarm as it continues Phase III trials. GTx has received encouraging news from early results from the trials, but doesn’t expect to report full results until early 2013.

In late January, Citigroup Inc. (NYSE: C) reported the early results, which caused the company’s stock price to increase nearly 50 percent to $5.88. Shares of the company’s stock are trading down about 35 percent to $3.78 Tuesday morning.

In a statement, Mitchell Steiner, CEO of GTx, said the company is still exploring “a path forward” to continue to develop Capesaris at lower doses.”

“We plan to work with the agency to design appropriate studies for these patient populations,” Steiner said.

“We are pleased with the progress of our clinical development program of Enobosarm, formerly known as Ostarine,” Steiner said. “Our discussions with lung cancer thought leaders and patient advocates confirm the need for a drug to prevent and treat muscle wasting in patients with advanced non-small cell lung cancer.”

StreetBeat Disclaimer

Distributed by Viestly